Additional file 1: Figure S1. of Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study

Flow cytometry analysis of cerebospinal fluid (CSF) samples of patients with breast cancer leptomeningeal metastasis. Representative dot plot and histogram for CSF breast cancer cells and tumor-associated leukocytes. (PPTX 2013 kb

Characteristics of patients.

<p>Characteristics of patients.</p

Overall survival.

<p>Kaplan Meier estimates of overall survival evaluated from the date of lapatinib-based therapy initiation in 132 patients according to PFS >7 months (solid line) or PFS ≤7 months (dashed line). Median overall survival is 36 months (95% C.I. 9–21 months) and 15 months (19–53 months), respectively (p<0.001).</p

Multivariate analysis for Progression-free survival (PFS) and Overall Survival (OS) from the start of lapatinib-based therapy.

<p>Multivariate analysis for Progression-free survival (PFS) and Overall Survival (OS) from the start of lapatinib-based therapy.</p

DataSheet_1_Effectiveness of a phone-based nurse monitoring assessment and intervention for chemotherapy-related toxicity: A randomized multicenter trial.docx

PurposeAnticancer treatment-related toxicities can impact morbidity and mortality, hamper the administration of treatment, worsen the quality of life and increase the burden on the healthcare system. Therefore, their prompt identification is crucial. NICSO (Italian Network for Supportive Care in Cancer) conducted a nationwide randomized trial to evaluate the role of a planned, weekly phone-based nurse monitoring intervention to prevent and treat chemotherapy, targeted therapy- and immunotherapy-related toxicities. Here, we report the results from the chemotherapy arm.MethodsThis was a nationwide, randomized, open-label trial conducted among 29 Italian centers (NCT04726020) involving adult patients with breast, colon, or lung cancer and a life expectancy ≥6 months receiving adjuvant chemotherapy. Patients received either a weekly nurse monitoring phone call and an educational leaflet reporting practical advice about prevention and treatment of toxicities (experimental group) or the educational leaflet only (control group).ResultsThe addition of a nurse monitoring intervention may help reduce time spent with severe toxicities (grade ≥3), particularly those less frequently reported in clinical practice, such as fatigue. When considering grade 1–2 AEs, times with mild/moderate diarrhea, mucositis, fatigue and pain were shorter in the experimental arm. Time spent without AEs was significantly longer in the experimental arms for all the toxicities. The requirement for special medical attention was comparable between groups.ConclusionThis study suggests the need for implementing a better system of toxicity assessment and management for patients treated with adjuvant chemotherapy to promote effective preventive and/or therapeutic intervention against these events.</p

Additional file 1 of TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication

Supplementary Material 1

Adjuvant systemic therapies.

<p>AST: adjuvant systemic therapy; CT: chemotherapy; HT: hormone therapy</p><p>Adjuvant systemic therapies.</p

Local-regional treatments.

<p>AST: adjuvant systemic therapy</p><p>Local-regional treatments.</p

Clinicopathologic characteristics and univariate analysis.

<p>LVI: lymphovascular invasion; HR: hormone receptor; AST: adjuvant systemic therapy; ER: estrogen receptor; PgR: progesteron receptor</p><p>*p-value according to Kruskal-Wallis, Chi square test or Fisher’s exact test, as appropriate</p><p>Clinicopathologic characteristics and univariate analysis.</p

A. Disease-free survival according to treatment group. Fig 1A shows Kaplan Meier’s disease-free survival curves according to treatment group. B. Disease-free survival according to stage. Fig 1B shows Kaplan Meier’s disease-free survival curves according to stage; the analysis was performed on 301 patients, since data on stage were missing for 2 patients.

<p>A. Disease-free survival according to treatment group. Fig 1A shows Kaplan Meier’s disease-free survival curves according to treatment group. B. Disease-free survival according to stage. Fig 1B shows Kaplan Meier’s disease-free survival curves according to stage; the analysis was performed on 301 patients, since data on stage were missing for 2 patients.</p